Developing Novel Oral Enzyme Therapies for Malabsorption Diseases

Realign

your expectations of oral enzymes.

Reimagine

how diseases of malabsorption and nutrient metabolism can be treated.

Rethink

what's possible.

We are...

Malabsorption syndromes and nutrient metabolism disorders are debilitating conditions affecting infants, children, and adults worldwide.

These diseases may not be properly treated or have no treatment at all.

Anagram Therapeutics is committed to changing that.

Realign

your expectations of oral enzymes.

Reimagine

how diseases of malabsorption and nutrient metabolism can be treated.

Rethink

what's possible.

breakthrough orally-delivered enzyme therapeutics
engineered for rare, life-threatening diseases.

Unlocking

breakthrough orally-delivered enzyme therapeutics
engineered for rare, life-threatening diseases.

We are Anagram.

learn more

Anagram is focused on becoming the world’s leading biopharmaceutical company developing breakthrough orally-delivered enzymes to treat diseases that have a severe impact on the lives of infants, children and adults as well as their families.

Watch Video

Through Anagram Therapeutics’ specific and selective approach, our team of world-class researchers and collaborators is unlocking breakthrough orally-delivered enzyme therapeutics that have the potential to change how Malabsorption Syndromes and Nutrient Metabolism Disorders are treated.

Our Science

Together, we are working to turn potential into products, and meaningfully improve the lives of people living with Malabsorption Syndromes and Nutrient Metabolism Disorders.